P2RY12 and COVID-19: To unravel the contribution of primary and secondary hemostasis to adverse effects in COVID-19, we analyzed the association of anticoagulation (LMWH and/or NOAC) or antiplatelet therapy (aspirin and/or P2Y12 blockers) with patient survival in a retrospective cohort comprising 578 consecutive patients with COVID-19.